



# 2021 Taipei International Breast Cancer Symposium

## 台北國際乳癌研討會

---

### **Considerations of the management of Asian postmenopausal women with ER+/HER2- advanced breast cancer**

Wei-Pang Chung, M.D.  
Clinical Assistant Professor,  
Department of Oncology,  
National Cheng Kung University Hospital,  
College of Medicine,  
National Cheng Kung University,  
Tainan, Taiwan

Breast cancer is the leading malignancy among women worldwide. In Asian countries, the incidence of breast cancer is increasing. Even with adequate treatments, around 30% of early-stage breast cancer patients still develop recurrent disease. Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) subtype accounts for the majority of metastatic breast cancer population. Adding cyclin-dependent kinase (CDK) 4/6 inhibitor to endocrine therapy improves progression-free survival in HR+/HER2- advanced breast cancer. This talk will be aimed to review the treatment efficacy and toxicity of endocrine therapy with and without CDK4/6 inhibitors. The data of the CDK4/6 inhibitor, Palbociclib, in Asian patients with HR+/HER2- metastatic breast cancer will be updated, which can further provide guidance on the use of palbociclib in these patients.